Información:
Error:
ID
34179
Descripción
Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.; ODM derived from: https://clinicaltrials.gov/show/NCT02334709
Link
https://clinicaltrials.gov/show/NCT02334709
Palabras clave
Versiones (1)
- 15/1/19 15/1/19 -
Titular de derechos de autor
GSK group of companies
Subido en
15 de enero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Carcinoma, Renal Cell NCT02334709
Eligibility Carcinoma, Renal Cell NCT02334709
- StudyEvent: Eligibility
Similar models
Eligibility Carcinoma, Renal Cell NCT02334709
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
ID.1
Item
signed informed consent
boolean
ID.2
Item
diagnosis of rcc with clear-cell component histology
boolean
ID.3
Item
at least 3 extracranial measurable metastatic lesions per recist
boolean
ID.4
Item
karnofsky performance score >60
boolean
ID.5
Item
patients should have undergone cytoreductive treatment of their rcc at least 6 weeks prior to inclusion
boolean
ID.6
Item
patients should have adequate organ function for tki treatment.
boolean
ID.7
Item
prior systemic treatment for rcc
boolean
ID.8
Item
uncontrolled central nervous metastases
boolean
ID.9
Item
prior radiotherapy interfering with sbrt
boolean
ID.10
Item
any disorder precluding understanding of trial information.
boolean